Pharmaceuticals
CStone Reports 2024 Interim Results and Recent Corporate Updates
* Total revenue of RMB 254.2 million for 2024 H1; achieving first-time profitability with cash reserve atRMB 814 million as of June 30, 2024. * NDA approval of sugemalimab (PD-L1) for Stage IV NSCLC in EU, marking the first successful international approval of aChina domestic anti-PD-L1 mAb. ...
2024-08-23 22:20
10701
Antengene Announces 2024 Interim Financial Results, Highlights Progress in R&D and Commercialization
SHANGHAI and HONG KONG, Aug. 23, 2024 /PRNewswire/ -- Antengene Corporation (6996.HK) today announced its interim results for the period endingJune 30, 2024 , along with several significant milestones achieved in recent months. Dr. Jay Mei, Antengene's Founder, Chairman, and CEO, stated, "In the...
2024-08-23 12:32
5361
Ascentage Pharma Announces 2024 Interim Results
ROCKVILLE, Md. and SUZHOU, China, Aug. 22, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing both first-in-class and best-in-class therapies for malignancies, today announced its 2024 interim results. During ...
2024-08-22 23:36
7804
Telix 2024 Half-Year Results: Strong Commercial Revenue and Profit Growth to Support Strategic Priorities
MELBOURNE, Australia, Aug. 22, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces its financial results for the half-year ended30 June 2024. All figures are in AU$ unless otherwise stated.[1] H1 2024 financial highlights * Total Group revenue o...
2024-08-22 17:04
3131
Inaugural Process Innovation Asia Pacific to Drive Industry Transformation for South-East Asia's Chemicals and Pharmaceuticals
SINGAPORE, Aug. 22, 2024 /PRNewswire/ -- Organised by Constellar, in partnership with DECHEMA Ausstellungs-GmbH (DECHEMA Exhibitions)[1], the inauguralProcess Innovation Asia Pacific - Powered by ACHEMA (PIA) will be held from19 to 21 November 2024 at Singapore EXPO. The most comprehensive Pr...
2024-08-22 15:30
10604
China's First Approved KRAS G12C Inhibitor: Innovent Announces the Approval of Dupert® (Fulzerasib) by the National Medical Products Administration of China
SAN FRANCISCO and SUZHOU, China, Aug. 22, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune...
2024-08-22 08:00
5129
Targeted Pre-Launch Scientific Outreach Drives 40% Faster Treatment Adoption
New Veeva Pulse findings show congresses and early-career experts have the
strongest influence on patient outcomes
SINGAPORE, Aug. 21, 2024 /PRNewswire/ -- Veeva Systems
2024-08-21 09:00
5508
Kelun-Biotech's TROP2-ADC SKB264 (sac-TMT) Second NDA Accepted by NPMA, locally advanced or metastatic EGFR-mutant NSCLC
CHENGDU, China, Aug. 20, 2024 /PRNewswire/ -- On August 20, the new drug application (NDA) for the core product sacituzumab tirumotecan (sac-TMT, formerly SKB264/MK-2870) based on the positive results from the pivotal OptiTROP-Lung03 study has been accepted by the Center for Drug Evaluation (CDE)...
2024-08-20 16:32
3258
Infinitus Highlights Modernizing Traditional Prescriptions at ICMCM
GUANGZHOU, China, Aug. 20, 2024 /PRNewswire/ -- Recently, the highly-anticipated 23rd International Conference of the Modernization of Chinese Medicine & Health Products (ICMCM) took place inHong Kong, bringing together global experts, top researchers and industry leaders in traditional medicine...
2024-08-20 15:09
3328
Alphamab Oncology Reports 2024 Interim Results and Business Highlights
SUZHOU, China, Aug. 16, 2024 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) reported interim financial results for the six months endedJune 30, 2024 and highlighted recent business progress. Financial Summary * For the six months ended June 30, 2024, we recorded total revenue of RMB ...
2024-08-16 11:18
4597
NANOFORM COLLABORATES WITH TAKEDA ON THEIR PLASMA-DERIVED THERAPY DEVELOPMENT
HELSINKI, Aug. 15, 2024 /PRNewswire/ -- Nanoform Finland Plc ("Nanoform"), the medicine performance-enhancing company, today announced that it is to enter into a pre-clinical development agreement with the Plasma-derived Therapies Business Unit of Takeda Pharmaceuticals, Inc., the R&D-driven biop...
2024-08-15 13:43
2596
Docquity Drives Demand for SIT Pharma's Duo Probiotics in Thailand, Achieving 31% Sales Growth in 6 months
* Docquity's Awareness to Advocacy (A2A) Program and strong local distribution network enabled SIT's duo probiotic sales to surpass the market growth rate of 15% * The technology platform boosted SIT's HCP education efforts, more than doubling its reach to 2,000 HCPs within six months and aim...
2024-08-13 10:00
3546
Registrational Phase III Study of Lisaftoclax in Newly-Diagnosed Patients with Higher-Risk Myelodysplastic Syndrome Cleared by China CDE
ROCKVILLE, Md. and SUZHOU, China, Aug. 13, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global, integrated biopharmaceutical company engaged in discovering, developing and commercializing both first- and best-in-class therapies for malignancies, announced today it has been cleared by the Ce...
2024-08-13 09:52
4581
Biosyngen's BRG01 Receives FDA Approval for Phase II Clinical Trial
SINGAPORE, Aug. 13, 2024 /PRNewswire/ -- Biosyngen is proud to announce that the U.S. Food and Drug Administration (FDA) has approved its BRG01, an EBV-specific CAR-T cell therapy, to proceed with a pivotal Phase lI clinical trial.This marks the first cell therapy to enter Phase lI trials in both...
2024-08-13 09:00
2918
AI in the IVF Process is the Standard of Care at Virtus Fertility Centre Singapore
The technology developed by Virtus Health's scientists contributes to IVF medicine by shortening the time to a successful pregnancy and improving overall success rates. SINGAPORE, Aug. 13, 2024 /PRNewswire/ -- Virtus Fertility Centre Singapore (VFCS) announced that artificial intelligence (AI), ...
2024-08-13 08:44
3145
Lynk Pharmaceuticals Announces Positive Results from Phase 1b Clinical Study of LNK01004 for the Treatment of Atopic Dermatitis
HANGZHOU, China and SHANGHAI and BOSTON, Aug. 13, 2024 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as "Lynk Pharmaceuticals"), a clinical-stage innovative drug development company, announced positive results from its Phase1b clinical study of LNK01004, a skin restricte...
2024-08-13 08:00
7068
Environmental Compliance and Pharmaceutical Quality Standards Pave the Way for Transformational Growth in Chromatography
SAN ANTONIO, Aug. 13, 2024 /PRNewswire/ -- Chromatography instruments and modular test equipment are revolutionising scientific analysis and industrial testing. By enabling precise separation and analysis of complex mixtures, chromatography plays a crucial role in ensuring pharmaceutical purity, ...
2024-08-13 01:30
2667
OcuMension acquires rights to Alcon eye drops in exchange for a 16.7% equity stake, signaling the commencement of comprehensive strategic relationship
SHANGHAI, Aug. 12, 2024 /PRNewswire/ -- On August 13th 2024, Ocumension Therapeutics ("OcuMension") announced an agreement with Alcon Inc. ("Alcon", and collectively with OcuMension, the "Parties") where OcuMension will acquire or secure commercialization rights inChina to a portfolio of Alcon dr...
2024-08-12 22:01
3782
Ocumension (01477.HK) Demonstrates Strong Operational Resilience, Commercialization Capabilities Reach New Heights
SHANGHAI, Aug. 12, 2024 /PRNewswire/ -- On August 12, Ocumension Therapeutics ( Shanghai) Co., Ltd. (01477.HK, hereinafter referred to as "Ocumension" or the "Company") released its 2024 Interim Results Report. During the reporting period, the company achieved operating revenue ofRMB 168 million, ...
2024-08-12 21:52
4316
Alphamab Oncology to Present the Latest Clinical Data of Anti-HER2 Bispecific ADC JSKN003 at the ESMO Congress 2024
SUZHOU, China, Aug. 12, 2024 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the latest clinical data from two studies on anti-HER2 bispecific antibody-drug conjugate (ADC) JSKN003 in patients with platinum-resistant ovarian cancer and patients with advanced HER2-positive (...
2024-08-12 10:18
3169
Week's Top Stories
Most Reposted
Agoda Begins Limited Public Beta of New AI Assistant That Turns Travel Ideas into Bookable Trips
[Picked up by 289 media titles]
2026-09-15 11:00
Avnet and The University of Hong Kong Open EMUS Lab to Accelerate AI Innovation and Commercialization in Hong Kong
[Picked up by 281 media titles]
2026-09-17 13:09
Sovereign Investment Institutions Launch China-ASEAN Joint Investment Council
[Picked up by 267 media titles]
2026-09-16 09:09
USSEC Advances Aquaculture Feed Formulation in Asia
[Picked up by 264 media titles]
2026-09-17 09:00
CLP Power Hosts AESIEAP CEO Conference 2026 in Hong Kong
[Picked up by 260 media titles]
2026-09-15 19:07
Most Read
ALLSWIFIT Introduces ActiveRise+, a Stable Carbon-Plate Running Shoe Built to Help Everyday Runners Train Smarter and Run Stronger
2026-09-11 21:00
14489
Cheetah Mobile Announces Second Quarter 2026 Unaudited Consolidated Financial Results
2026-09-11 10:36
10585
